The National Institute for Health Research has awarded £2 million to the University of Liverpool’s Epilepsy Research Group for a clinical trial to assess new treatments for the condition.
The programme, SANAD II, will aim to recruit over 1,500 patients for the trial to identify whether new medicines should become “first-line treatments”. The trial is also supported by the Walton Centre NHS Foundation Trust.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.